Setidegrasib is a targeted protein degrader that prompts cancer cells to destroy mutant KRAS rather than merely inhibiting it. By recruiting the ubiquitin–proteasome system, the drug marks mutant KRAS for degradation, potentially yielding longer-lasting suppression and reducing some forms of drug resistance. This strategy may expand the range of treatable targets, but clinical trials are required to confirm safety, durability and which cancers benefit most.
New Cancer Strategy: Setidegrasib—A Drug That Destroys Mutant KRAS Instead of Just Blocking It
Human Cancer Cellgetty
A novel drug strategy destroys one of cancer's most common driver proteins rather than merely blocking its activity, highlighting the promise of a growing class of medicines called targeted protein degraders.
Setidegrasib targets mutant forms of KRAS, a protein whose common mutations drive many pancreatic, colorectal and lung cancers by locking KRAS into an always-on state that promotes uncontrolled cell growth. Unlike conventional inhibitors that temporarily block KRAS signaling, Setidegrasib recruits the cell's quality-control machinery to remove the mutant protein entirely.
How Targeted Protein Degraders Work
Traditional targeted drugs act like caps on a keyhole: they bind a protein and stop it from functioning while they remain attached. When they dissociate, the protein can regain activity. Targeted protein degraders take a different route by harnessing the ubiquitin–proteasome system—the cell's natural pathway for tagging and recycling unwanted proteins.
Degraders bring the disease-causing protein into proximity with an E3 ubiquitin ligase, an enzyme that attaches small ubiquitin tags to the target. Those tags send the protein to the proteasome, the cell's recycling center, where the protein is dismantled. After degradation, the degrader molecule can be released and reused to target additional protein molecules.
Setidegrasib: Designed to Recognize Mutant KRAS
Setidegrasib was engineered to recognize pockets that form only when KRAS carries certain oncogenic mutations. This mutation-dependent binding helps the compound preferentially target mutant KRAS in cancer cells while largely sparing normal, wild-type KRAS in healthy tissue. After binding, Setidegrasib recruits an E3 ligase to tag KRAS with ubiquitin and send it to the proteasome for destruction.
Because one Setidegrasib molecule can catalyze the degradation of multiple KRAS copies before being recycled, the approach can produce sustained suppression of signaling until the cell synthesizes new KRAS protein.
Potential Advantages and Limitations
Destroying the protein rather than merely inhibiting it may: (1) prolong drug effect because the target must be re-synthesized, (2) reduce some mechanisms of resistance that arise when mutations reduce inhibitor binding, and (3) expand the range of "druggable" proteins because degraders do not always require a tightly blocking binding site.
However, important caveats remain. Tumors could still evolve resistance via other mechanisms (for example, mutations that prevent degrader binding or alterations in ubiquitin machinery). Safety must be carefully evaluated in clinical trials to confirm that removing specific proteins does not cause unacceptable toxicity in normal tissues.
What Comes Next
Setidegrasib provides one of the clearest demonstrations so far that targeted protein degradation can be applied to mutant KRAS and, more broadly, to difficult-to-drug oncoproteins. Ongoing and future clinical studies will determine which KRAS-driven cancers respond best, which mutations are most susceptible, and how durable responses will be. If successful, targeted degradation could reshape drug discovery by enabling removal of pathogenic proteins previously considered undruggable.
For decades, drug discovery focused on blocking proteins. Targeted protein degradation points toward a next generation of therapies that remove harmful proteins altogether.
Help us improve.
